HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.

Autor:	Seaton KE; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Ballweber L; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America., Lan A; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Donathan M; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Hughes S; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America., Vojtech L; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America., Moody MA; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Liao HX; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Haynes BF; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Galloway CG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Richardson BA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America., Karim SA; CAPRISA - Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, New York, United States of America., Dezzutti CS; Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America; Department of Global Health, University of Washington, Seattle, Washington, United States of America., Tomaras GD; Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Hladik F; Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America.
Jazyk:	angličtina
Zdroj:	PloS one [PLoS One] 2014 Jul 23; Vol. 9 (7), pp. e101863. Date of Electronic Publication: 2014 Jul 23 (Print Publication: 2014).
DOI:	10.1371/journal.pone.0101863
Abstrakt:	Background: Many participants in microbicide trials remain uninfected despite ongoing exposure to HIV-1. Determining the emergence and nature of mucosal HIV-specific immune responses in such women is important, since these responses may contribute to protection and could provide insight for the rational design of HIV-1 vaccines. Methods and Findings: We first conducted a pilot study to compare three sampling devices (Dacron swabs, flocked nylon swabs and Merocel sponges) for detection of HIV-1-specific IgG and IgA antibodies in vaginal secretions. IgG antibodies from HIV-1-positive women reacted broadly across the full panel of eight HIV-1 envelope (Env) antigens tested, whereas IgA antibodies only reacted to the gp41 subunit. No Env-reactive antibodies were detected in the HIV-negative women. The three sampling devices yielded equal HIV-1-specific antibody titers, as well as total IgG and IgA concentrations. We then tested vaginal Dacron swabs archived from 57 HIV seronegative women who participated in a microbicide efficacy trial in Southern Africa (HPTN 035). We detected vaginal IgA antibodies directed at HIV-1 Env gp120/gp140 in six of these women, and at gp41 in another three women, but did not detect Env-specific IgG antibodies in any women. Conclusion: Vaginal secretions of HIV-1 infected women contained IgG reactivity to a broad range of Env antigens and IgA reactivity to gp41. In contrast, Env-binding antibodies in the vaginal secretions of HIV-1 uninfected women participating in the microbicide trial were restricted to the IgA subtype and were mostly directed at HIV-1 gp120/gp140.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF